Why is progress in acute myeloid leukemia so slow?

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 243-248

  Estey, Elihu ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; ASSAY; CHEMOTHERAPY; CLINICAL STUDY; CONVENTIONAL CHEMOTHERAPY; DRUG APPROVAL; EVENT FREE SURVIVAL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; XENOTRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GENETICS; PATHOLOGY; RECURRENT DISEASE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; RECURRENCE;

EID: 84937408042     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.03.007     Document Type: Review

References (40)

1. Topp M.S., Gökbuget N., Stein A.S., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015, 16:57-66.
2. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet Oncol 2015, 385:517-528.
3. Byrd J.C., Jones J.J., Woyach J.A., Johnson A.J., Flynn J.M. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 2014, 32:3039-3047.
4. Cortes J.E., Kim D.W., Pinilla-Ibarz J., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
5. Lo-Coco F., Avvisati G., Vignetti M., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
6. Othus M., Kantarjian H.M., Petersdorf S., et al. Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia (AML) given "intensive" induction regimens: a report from the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). Leukemia 2014, 28:289-292.
7. Lancet J.E. New agents: great expectations not realized. Best Pract Res Clin Haematol 2013, 26:269-274.
8. Pizzitola I., Anjos-Afonso F., Rouault-Pierre K., et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014, 28:1596-1605.
9. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074.
10. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
11. Klco J.M., Spencer D.H., Miller C.A., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25(3):379-392.
12. Duque-Afonso J., Cleary M.L. The AML salad bowl. Cancer Cell 2014, 25(3):265-267.
13. Kronke J., Bullinger L., Teleanu V., et al. Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia. Blood 2013, 122:100-108.
14. Markstein M. Modeling colorectal cancer as a 3-dimensional disease in a dish: the case for drug screening using organoids, zebrafish, and fruit flies. Drug Discov Today Technol 2013, 10(1):e73-e81.
15. Walsh A.J., Cook R.S., Sanders M.E., et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res 2014, 74:5184-5194.
16. Estey E. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 2013, 27:1803-1812.
17. Jabbour E.J., Hughes T.P., Cortes J.E., Kantarjian H.M., Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 2014, 55:1451-1462.
18. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
19. Giles F.J., Kantarjian H.M., le Coutre P.D., et al. Nilotinib is effective in imatinib-resistant or intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012, 26:959-962.
20. Cortes J., Kim D.W., Raffoux E., et al. Efficacy and safety of dasatinib in imatinib resistant or intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22:2176-2183.
21. Jiang H., Xu L.P., Liu D.H., et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014, 49:1146-1154.
22. Appelbaum F.R., Gendacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
23. Yanada M, Garcia-Manero G., Borthakur G., Ravanadi F., Kantarjian H., Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 2008, 93:633-634.
24. Thall P.F. Bayesian models and decision algorithms for complex early phase clinical trials. Stat Sci 2010, 25:227-244.
25. Rogatko A., Babb J.S., Tighiouart M., Khuri F.R., Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res 2005, 11:5342-5346.
26. Galanis A., Ma H., Rajkhowa T., et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014, 123:94-100.
27. Estey E. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 2014, 89:1063-1081.
28. Gyurkocza B., Storb R., Storer B.E., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
29. Chen X., Xie H., Wood B., et al. The relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 2015, 33:1258-1264.
30. Adnane L., Trail P.A., Taylor I., Wilhelm S.M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006, 407:597-612.
31. Röllig C., Müller-Tidow C., Hüttmann A., et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. Blood 2014, 124:6. (ASH abstract 6).
32. Cortes J., Perl A., Dombret H., et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood 2012, 120:48. (ASH abstract 48).
33. Marcucci G., Geyer S., Zhao W., et al. Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance). Blood 2014, 124:8. (ASH abstract 8).
34. Social Security Administration. Retirement & survivors benefits: life expectancy calculator. Accessed at . http://ssa.gov/oact/population.
35. Estey E., Thall P. New designs for phase 2 trials. Blood 2003, 102:442-448.
36. Hills R., Burnett A. Applicability of a "pick a winner" trial design to acute myeloid leukemia. Blood 2011, 118:2389-2394.
37. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase III study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121. 4854-60.
38. Hills R.K., Castaigne S., Appelbaum F.R., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014, 15:986-996.
39. Ravandi F., Estey E.H., Appelbaum F.R., et al. Gemtuzumab ozgamicin: time to resurrect?. J Clin Oncol 2012, 30:3921-3923.
40. Luskin M., Lee J.-W., Rowe J., et al. Results of the ECOG E1900 trial in younger adults with AML using an event free survival endpoint are concordant with results based on overall survival: potential for a surrogate endpoint to facilitate rapid approval of therapies in AML. Blood 2014, 124:2599. (ASH abstract 2599).